Skip to main content
Pharnext logo

Pharnext — Investor Relations & Filings

Ticker · ALPHA ISIN · FR0011191287 LEI · 969500KJGF9ZUYXSMJ27 Euronext Growth Manufacturing
Open in API
Filings indexed 382 across all filing types
Latest filing 2016-12-20 Regulatory Filings
Country FR France
Listing Euronext Growth ALPHA

About Pharnext

https://pharnext.com/

Pharnext is an advanced clinical-stage biopharmaceutical company that develops novel therapeutics for neurodegenerative diseases lacking curative or satisfactory treatments. The company's approach is based on its proprietary Pleotherapy™ platform, which uses network pharmacology to identify and develop synergistic combinations of already-approved drugs at new, lower doses. This strategy aims to create more effective and safer treatments. Pharnext's lead product candidate, PXT3003, is an oral fixed-dose combination therapy in development for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A), a rare, debilitating inherited peripheral neuropathy.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 1% confidence The document is a press release dated December 20, 2016, announcing a specific operational milestone: the completion of patient enrollment for the Phase 3 clinical trial (PLEO-CMT) of their drug candidate PXT3003. It contains quotes from management and external experts, details about the trial design, and contact information. This type of announcement, focusing on clinical trial progress and operational updates rather than comprehensive financial results (like a 10-K or IR) or formal regulatory filings, is best classified as a general announcement. Since it is not a formal earnings release (ER), a management discussion (MDA), or a specific regulatory filing like DIRS or DIV, and it is not announcing the publication of a full report (RPA), the most appropriate general category for this type of corporate/operational news release is Regulatory Filings (RNS), which serves as a broad category for significant, non-financial, non-meeting-related announcements.
2016-12-20 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and announces a specific operational milestone: the completion of patient recruitment for a Phase 3 clinical trial (PLEO-CMT) for the drug PXT3003. It provides details about the trial design, next steps (results expected in H2 2018), quotes from management and external experts, and contact information. This type of announcement, focusing on key operational or clinical progress rather than full financial results (like a 10-K or ER) or a formal regulatory filing document, is best classified as an Earnings Release (ER) if it were quarterly results, but since it is a specific operational update often released outside of standard earnings cycles, it fits best under the general category of an initial announcement of key information. Given the options, an Earnings Release (ER) often encompasses significant operational updates that drive investor interest, even if not strictly quarterly financials. However, since this is a clinical trial update, it is a specific type of corporate news. It is not a full financial report (10-K, IR), a transcript (CT), or a presentation (IP). It is a formal announcement of a significant event. In many databases, major clinical trial updates are often grouped with Earnings Releases or treated as Regulatory Filings (RNS). Since it is a formal press release detailing a major operational milestone, and it is not a short announcement pointing to another document (RPA), it is a primary disclosure. Given the choices, 'ER' (Earnings Release) is often used broadly for major periodic announcements, but 'RNS' (Regulatory Filings) is the most appropriate fallback for significant, non-financial, non-presentation corporate news that must be disclosed to the market, especially in a European context where press releases serve this function. Given the context of a clinical trial update, which is material information, RNS is the safest classification if ER is reserved strictly for financial results. Since the document is a detailed press release announcing a major clinical milestone, I will classify it as a Regulatory Filing (RNS) as it is a mandatory disclosure of material information that doesn't fit other specific categories like ER or CT.
2016-12-20 French
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Earnings Release Classification · 1% confidence The document is a press release ("Communiqué de presse") announcing positive data from a Phase 2 exploratory clinical trial (PLEODIAL®) for the drug PXT864 in Alzheimer's disease, which was presented at the CTAD conference. This type of announcement, detailing clinical trial results and scientific findings, is characteristic of an Earnings Release (ER) if it were focused on financial performance, or potentially an Investor Presentation (IP) if it were a slide deck. However, since it is a formal announcement of scientific/clinical progress and results, and not a comprehensive periodic financial report (like 10-K or IR), it best fits the category for initial results announcements. Given the content focuses on clinical efficacy and safety data presentation at a conference, it is most closely aligned with an Earnings Release (ER) which often includes operational highlights, or an Investor Presentation (IP) if it were structured as such. Since it is a press release detailing key results, it functions as an announcement of operational/scientific progress. In the context of the provided definitions, it is not a full financial report (10-K, IR), nor a transcript (CT), nor a formal regulatory filing (RNS). It is a release of key operational/scientific information. While it contains scientific data, it is structured as a news announcement. If the company regularly issues such scientific updates outside of formal earnings, it often defaults to ER or IP. Given the structure and purpose (announcing key data points), ER is a strong candidate for operational updates, but IP is also plausible for detailed scientific updates. Since it is a press release announcing data presented at a conference, and not a formal periodic financial report, I will classify it as an Earnings Release (ER) as it communicates key performance/progress indicators, or potentially an Investor Presentation (IP) if the focus was purely strategic/data-heavy. Given the strong focus on clinical trial results, Investor Presentation (IP) is a slightly better fit than a general Earnings Release (ER) which usually focuses on revenue/profit. However, many companies use ERs for major clinical trial updates. Let's re-evaluate: It is a press release announcing data presented at a conference. This is a common format for an Earnings Release (ER) or a specific scientific update. Since it is not a comprehensive report (IR/10-K) or a presentation deck (IP), and it announces key progress, ER is the most appropriate general category for significant operational/scientific announcements outside of formal reporting periods. I will lean towards ER as it is a formal press release announcing key findings, similar to how earnings are announced, but I acknowledge IP is close. Given the lack of explicit financial figures (revenue, profit), IP might be better. Let's check IP definition: 'Detailed presentation for investors focusing on financials, strategy, and market position.' This press release details strategy (PLEOTHERAPIE) and clinical position. I will select IP as the primary classification due to the deep dive into clinical trial methodology and results, which is typical content for an investor presentation, even if delivered via a press release format. FY 2016
2016-12-13 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Earnings Release Classification · 1% confidence The document is a press release announcing positive exploratory Phase 2 clinical trial data for a drug candidate (PXT864) for Alzheimer's disease, presented at a conference (CTAD). It details efficacy, safety, and future development plans. This content is characteristic of an Earnings Release (ER) or a general announcement related to clinical progress, but it is not a formal regulatory filing like a 10-K, a comprehensive Interim Report (IR), or a specific shareholder communication like a DEF 14A. Since it is a press release detailing key financial/operational results (clinical trial outcomes), the most appropriate classification among the provided options is Earnings Release (ER), as these often include operational highlights that drive investor interest, even if they aren't quarterly financial figures. It is not a Call Transcript (CT) or a formal Investor Presentation (IP). Given the nature of announcing trial results, ER is the best fit for a high-level operational update. FY 2016
2016-12-13 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Investor Presentation Classification · 1% confidence The document is a press release ("Communiqué de presse") from the biopharmaceutical company Pharnext. It announces that Phase 2 clinical trial data for their drug PXT864 (for Alzheimer's disease) will be presented at the 9th Clinical Trials on Alzheimer's Disease (CTAD) conference. The text details the presentation schedule (oral and poster sessions) and provides background information on the drug and the disease. This type of announcement, detailing the presentation of scientific or clinical data at a specific industry event, is characteristic of an Investor Presentation (IP) or a general announcement related to clinical progress. Since it is a formal announcement detailing upcoming presentation of clinical data and strategy context, it aligns best with the Investor Presentation (IP) category, which often includes updates on clinical pipeline progress, rather than just a brief Earnings Release (ER) or a general Regulatory Filing (RNS). It is not a full report (10-K, IR) nor a transcript (CT).
2016-12-01 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Investor Presentation Classification · 1% confidence The document is a press release announcing that the company, Pharnext, will present Phase 2 clinical trial data for its drug PXT864 at an upcoming medical conference (CTAD). It details the presentation times, the study design (PLEODIAL-I and II), and provides background information on the drug and the disease. This type of announcement, which publicizes upcoming scientific presentations or data releases, is best classified as an Investor Presentation (IP) if it were a detailed deck, or more generally, a communication aimed at investors and the public about ongoing development activities. Since it is a press release detailing scientific data presentation schedules rather than a formal regulatory filing (like 10-K or IR) or a transcript of a call, and it focuses on clinical trial updates, it aligns closely with the purpose of an Investor Presentation (IP) which often includes such updates, or potentially a Regulatory Filing (RNS) if no better fit exists. However, given the focus on presenting clinical trial data at a scientific meeting, 'Investor Presentation' (IP) is a strong fit as these announcements are crucial for investor communication regarding R&D progress. It is not a Call Transcript (CT), Earnings Release (ER), or a formal report (10-K, IR). It is an announcement about future data presentation, which is a common component of investor relations materials.
2016-12-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.